22^nd World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry June 24-25, 2022 Berlin, Germany

Biography:

Thomas J. Webster’s (H index: 108; Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has served as a professor at Purdue (2000-2005), Brown (2005-2012), and Northeastern (2012-2021; serving as Chemical Engineering Department Chair from 2012 - 2019) Universities and has formed over a dozen companies who have numerous FDA approved medical products currently improving human health.  Dr. Webster has numerous awards including: 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Materials Science and Mixed Fields); 2021, Clarivate Top 0.1% Most Influential Researchers (Pharmacology and Toxicology); and is a fellow of over 8 societies.

 

Abstract:

While advances in biomaterials have helped the lives of millions over the past century, it is clear that we are at a crossroads for the future of global healthcare. Considering the COVID-19 pandemic, constant struggles with cancer, and an emerging crisis in antibiotic resistant bacteria, to just name a few on-going healthcare problems, we need innovative ideas. Non-medical fields have advanced considerably in new material design, from using sensors to drive cars and touch screen pads for electronics. Innovation in biomaterials has been lagging behind. This presentation will cover some of the more innovative biomaterials than can meet today's challenges including the use of implantable sensors, 4D printed materials in which material shape can be controlled remotely after implantation, smart nanomaterials that can seek out and passivate viruses and bacteria, and so much more. This presentation will also lay the foundation for what is needed for future biomaterial design, especially obtaining regulatory approval for interactive biomaterials. This presentation will cover over 25 years of commercializing nanomaterials from an academic lab to real medical devices currently implanted into humans to aid in health.

Biography:

Shihab Uddin has received his PhD in Engineering on Chemical System and Engineering (leading to Biomedical Engineering) from the Kyushu University, Fukuoka, Japan in 2021. Currently, he is working in the Kyushu University, Fukuoka, Japan as a postdoctoral research fellow in the Dept. of Applied Chemistry and very soon he will join in the University of the British Columbia, Vancouver, Canada as a postdoctoral research fellow at the faculty of the Pharmaceutical Sciences. He is a highly motivated and innovated research scientist with demonstrated academic and industrial experienced in synthetic/material chemistry, pharmaceutical-formulations, nano biotechnology, and lipid-based nano drug delivery. He is expert in synthetic biology, methods developments and validations, pharmacokinetics, pharmacodynamics, drug delivery, and targeted tumor immune therapy. He is serving as an editorial board member of “Pharmacotherapy and Pharma science Discovery” journal. He has several publications in well repeated journal of RSC, ACS, Springer, and Elsevier and many of them are noted as front cover pages. He is focusing his research on the developing and translating innovative drug delivery technologies to clinical use and educating the next generation of scientist in the drug delivery field.

Abstract:

Ionic Liquids (ILs) are a novel class of environmentally benign and tailor-made solvents. They have been increasingly exploited as solvents, co-solvents, and/or materials in the fields of pharmaceutical drug delivery and Active Pharmaceutical Ingredient (API) formulation because of their unique properties. ILs ensures potent therapeutic action by solubilizing or stabilizing as well as enhancing skin penetration of drugs in Transdermal Drug Delivery Systems (TDDSs). We’ve developed three novel Lipid-Based Bio-Ils (LBILs), each including a long chain phosphonium cation, the phosphatidylcholine derivative named 1,2-dimyristoyl-sn-glycero-3-ethyl-phosphatidylcholine; EDMPC (similar to natural lipids on the skin) and a long-chain Fatty Acid (FA).  In the synthesis of LBILs, EDMPC Chloride (EDMPC-Cl) was first synthesized by a series of reactions under specific conditions. Then, the combination of equimolar amounts of either linoleic, oleic, or stearic acid with the EDMPC-Cl synthesize three LBILs, [EDMPC][Lin], [EDMPC][Ole], and [EDMPC][Ste]. At room temperature, [EDMPC][Lin], [EDMPC][Ole] and [EDMPC][Ste] are viscous liquid, highly viscous liquid and semi-solid respectively. The purity, thermal phase behavior, and identical properties of LBILs were optimized by proton nuclear magnetic resonance (¹H NMR), Fourier Transform Infrared (FTIR) spectroscopy, Differential Scanning Calorimetry (DSC), Elemental Analysis (EA), Mass Spectroscopy (MS), Dynamic Light Scattering (DLS) and UV visible spectroscopy. The three LBILs were found soluble at an equal ratio in both polar (ethanol, methanol, etc.) and non-polar solvents (hexane, heptane, etc.) solvents. DLS and UV analysis revealed that LBILs were molecularly soluble in nonpolar solvents and dispersible in polar solvents by forming microemulsions/ nanoparticles. Using an artificial three-dimensional human epidermis model these compounds were tested for biocompatibility in a well-established skin irritation test (MTT-assay) only to exhibit excellent biocompatibility. The Ionic-liquid-in-oil-nanodispersions (IL/O-NDs) from three LBILs enhanced the transdermal permeation of the peptide to the skin layers by deforming its lipid and protein arrangements to enhance the transdermal permeation of the peptide compared to other Conventional Skin Permeation Enhancers (CPE) and Tween-80. Transdermal peptide delivery profiles of IL/O-NDs of these three peptide-LBIL complexes revealed that [EDMPC][Lin]/O-ND was the most preferable for a TDDS based on the pharmacokinetic parameters compared to others. These results clearly state the assurance of enhanced TDDS by synthesis of these universal soluble biocompatible Ionic Liquids.

 

Biography:

Dr. (Mrs.) Anamika Singh is currently working as Sr. Assistant Professor in Department of Botany, Maitreyi College, University of Delhi. She has master’s degree in Botany from University of Allahabad and she has also completed, P.hD in Bioinformatics from Indian Institute of Information Technology, Allahabad (IIIT-A). During her studies she was awarded by National fellowship. She is having ten years teaching and research experience in different organizations. Her  area of research interest is Genetic Engineering, Molecular biology, Bioinformatics, Biological Databases, Phylogeny, Molecular modeling, Proteomics, Genomics, Drug Designing, Computer based Drug designing, Computational Biology, Sequence Analysis, Evolutionary Computing etc.  Dr. Singh is member of Indian Bioinformatics society, International Society for Infectious Diseases, APBioNet, European Federation of Biotechnology and IAENG. She is also actively involved as reviewing research articles of different journals. She has organized National, international conferences, faculty development programs and workshops in different platforms. She has published many research papers, book chapters in reputed journals and publishers.

 

Abstract:

India is a rich country, especially in terms of natural resources, Himalayan, Western Ghats and wide mountain range are the main vacillator of different plants of medicinal values. Many of these plants are describes perfectly in Ayurveda and till date it is widely used throughout country and worldwide by Ayurveda practitioners. 21^st century is the era, where sciences expands like anything but still there are much more hidden in terms of medicinal plants and their role. This article is focus on pharmacological aspects of Indian medicinal plants that are describes perfectly in Ayurveda. Modern medicines are completely experiment based and well documented and Indian medicinal plants are describes in the form of sutras that are in Sanskrit language, that may be a reason that few plants are still not well known in medical terms as Sanskrit is not easy to understand by everyone, so few basic examples can easy discussed and described in detail in the article.

 

Biography:

Dr. Chinmaya Mahapatra, completed his masters and Ph.D in Pharmacy. He is the founder president of Global Pharmacovigilance Society and Editor-in-chief of Journal of Pharmacovigilance and drug research. Currently he is working as an independent consultant for Clinexel Life sciences Pvt. Ltd. and ADR monitoring Center Co-ordinator at IMT Pharmacy College Puri, IPC- PvPI, Govt. of India. Dr. Mahapatra is having more than 10 years of experience in Pharmaceutical companies, Clinical research and pharmacovigilance. He has worked for Ciron Drugs, Mumbai, Ipca Laboratories Ltd, Silvassa as QA officer and Indian Pharmacopoeia Commission as Pharmacovigilance Associate.

 

Abstract:

Contract Research Organizations (CRO), are the backbone of most of the pharmaceutical companies for Clinical trials and Pharmacovigilance.  With the advancement of technology in the field of artificial intelligence and machine learning, the regulators are more keen towards the quality information about clinical trials. The testing of safety and efficacy of newly investigational drugs and drug products poses many challenges for pharmaceutical companies. Hence to overcome this challenge in a short span of time, a good CRO partner plays a vital role in supporting a pharmaceutical company to meet the regulatory requirements starting from IND filing to Post marketing surveillance. Selecting the best CRO for outsourcing a clinical trial is very important. The performance of a CRO is measured by on time completion of patient recruitments within projected cost, generation of high quality data and data integrity.

An ISO certified Company Clinexel life Sciences Pvt. Ltd is a CRO based in India with partners across the globe. It provides full services in the field of clinical trials, medical writing, regulatory affairs and pharmacovigilance. Clinexel is also a member of AICROS since July 2020 and it could be a great choice for pharmaceutical companies, Biotechnology companies and medical device manufacturing companies. Clinexel also supports academic clinical trials and Investigator initiated clinical trials.

Clinexel is conducting Phase 1, 2 and 3 Clinical Trials and complete Pharmacovigilance Operations. It is niche CRO supporting early stage RnD labs and small and mid- size pharma companies for fast and efficient clinical development of their medicinal products. Clinexel has a strong network of Clinical trial sites, Investigators and key opinion leaders. Clinexel has a strong regulatory team and successfully filed several Investigational New Drugs (INDs) and clinical trial applications (CTAs).